Replay develops genomic medicine platforms, led by uCell™, an off-the-shelf hypoimmunogenic technology for making allogeneic donor-derived primary cells and iPSCs immune silent. Its toolkit also includes a high-payload HSV delivery platform (synHSV™) and a proprietary genome writing platform. Replay says uCell™ can reduce cost-of-goods, improve product volume and consistency, enable extensive genome engineering, and broaden access to cell therapies across cancer, infectious diseases, neurodegenerative diseases, and regenerative medicine. The company operates a hub-and-spoke business model that separates technology development at Replay from therapeutic development in product companies and plans to progress uCell™ through therapeutic-area-focused product companies. Replay received non-dilutive support—a $1.56 million grant from the Bill & Melinda Gates Foundation—to accelerate uCell™ development, and previously raised $55 million in seed financing in July 2022. The company is headquartered in San Diego, California and London, UK, and is led by a team of academics, entrepreneurs, and industry experts. Replay develops genome writing and delivery technologies to enable large‑payload genetic reprogramming, assembling a toolkit that includes a high‑payload HSV platform, a hypoimmunogenic platform, and a genome writing platform. The company has also established an enzyme‑writing product company that leverages its evolutionary inference machine‑learning and genome‑writing technology to optimize functionality. Replay positions these platforms to address scientific challenges limiting clinical progress and to advance genomic medicine. Its leadership team includes experienced executives and pioneers in virology and synthetic biology, and the company lists multiple academic and industry advisors and co‑founders. The article does not disclose revenue or user metrics; the only financial detail provided is the recent fundraise.

Total raised

$57M

Funding rounds

2

Latest round

Grant

Latest activity

Nov 2022